Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity

PURPOSE: To evaluate the efficacy of a biosimilar ranibizumab (Razumab) on outcomes of retinopathy of prematurity (ROP) for the first time. METHODS: This retrospective study included infants presenting with stage 3+ ROP either in zone 1 or zone 2 posterior or aggressive posterior ROP (APROP). All el...

Descripción completa

Detalles Bibliográficos
Autores principales: Prajapati, Vipul, Choudhary, Tanvi, Chauhan, Wilhemina, Shah, Sonali, Handa, Ramya, Jahan, Bushra, Malviya, Sheetal, Sengupta, Sabyasachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228963/
https://www.ncbi.nlm.nih.gov/pubmed/36727329
http://dx.doi.org/10.4103/ijo.IJO_973_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228963/
https://www.ncbi.nlm.nih.gov/pubmed/36727329
http://dx.doi.org/10.4103/ijo.IJO_973_22

Ejemplares similares